Latest Entitlement Offer News

360 Capital Mortgage REIT reported a robust half-year performance with a 40.5% increase in gross assets and a targeted 10.4% distribution yield for FY26, underpinned by disciplined lending and solid capital raising.

360 Capital Mortgage REIT has reported a near doubling of its half-year profit to $2.6 million, driven by a 70% surge in investment income, alongside a successful $16.6 million capital raising. The Trust maintains a strong balance sheet with stable net asset value and a diversified loan portfolio.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Verity Resources is raising approximately $2 million through a non-renounceable entitlement offer to advance its Monument Gold and Botswana copper-silver projects, with directors backing the move through participation and underwriting.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Small caps did the heavy lifting this week, led by two big discovery stories in resources. Funding raises and takeover moves kept attention on who can pay for the next step, not just promise it.

Big moves came from consumer fintech names as investors quickly re-priced growth, losses, and capital needs. A capital-raise week also split the market: some raisings steadied prices, others triggered fresh selling.

Speculative money piled into new discoveries and tight-supply metals, while a handful of small caps were sold hard on thin liquidity. The week’s biggest moves came from PGMs and tungsten on the way up, and micro-cap gas on the way down.